Sugi Predict

Sugi Predict / Targets / FGFR4

FGFR4

Fibroblast growth factor receptor 4 · P22455 · FGFR4 on Sugi Atlas →

117,966 patent compounds predicted against FGFR4, 74,075 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Pd-173074 Pd-173074 (SCHEMBL177946) 1.00 16/20
Ly-2874455 Ly-2874455 (SCHEMBL297689) 1.00 13/20
Ly-2874455 Ly-2874455 (SCHEMBL297690) 1.00 13/20
Ly-2874455 Ly-2874455 (SCHEMBL298445) 1.00 13/20
Ly-2874455 Ly-2874455 (SCHEMBL298446) 1.00 13/20
SCHEMBL143675 SCHEMBL143675 1.00 9/20
SCHEMBL144665 SCHEMBL144665 1.00 9/20
SCHEMBL147279 SCHEMBL147279 1.00 9/20
SCHEMBL116925 SCHEMBL116925 0.73 9/20
SCHEMBL146452 SCHEMBL146452 0.72 9/20
SCHEMBL344501 SCHEMBL344501 0.69 9/20
SCHEMBL145725 SCHEMBL145725 1.00 8/20
SCHEMBL146609 SCHEMBL146609 1.00 8/20
SCHEMBL144476 SCHEMBL144476 0.74 8/20
SCHEMBL147746 SCHEMBL147746 0.74 8/20
SCHEMBL147378 SCHEMBL147378 0.72 8/20
SCHEMBL19506 SCHEMBL19506 0.53 8/20
SCHEMBL140758 SCHEMBL140758 1.00 7/20
SCHEMBL142058 SCHEMBL142058 0.83 7/20
SCHEMBL116862 SCHEMBL116862 0.73 7/20

Clinical trials — most relevant to FGFR4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Role of Coenzyme Q10 in Chronic Kidney Disease PHASE4RECRUITING
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy PHASE2UNKNOWN
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling PHASE2WITHDRAWN
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma PHASE2COMPLETED
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations PHASE2COMPLETED
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors PHASE2WITHDRAWN
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) PHASE2COMPLETED
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells PHASE2RECRUITING
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression PHASE1/PHASE2COMPLETED
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) PHASE2COMPLETED
A Study of TAS-120 in Patients With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma PHASE2COMPLETED
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14 PHASE2COMPLETED
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC PHASE2UNKNOWN
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations PHASE2COMPLETED
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma PHASE1RECRUITING
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) PHASE1COMPLETED
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations PHASE1RECRUITING
Phase 1 Study of E7090 in Subjects With Solid Tumor PHASE1COMPLETED
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations PHASE1COMPLETED
A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor PHASE1UNKNOWN
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations PHASE1RECRUITING
Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients nanRECRUITING
A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients nanUNKNOWN
Role of FGF21 in Breast Cancer nanNOT_YET_RECRUITING
Erdafitinib in Metastatic Steroid-cell Ovarian Cancer nanCOMPLETED
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a FGFR4 binder may also engage these)

ProteinNameSimilarity
Q03142 — 1.000 Q03142 →
Q498D6 — 1.000 Q498D6 →
FGFR3 Fibroblast growth factor receptor 3 0.995 landscape →
P55146 — 0.992 P55146 →
P55144 — 0.990 P55144 →
Q90330 — 0.989 Q90330 →
TYRO3 Tyrosine-protein kinase receptor TYRO3 0.988 landscape →
Q91288 — 0.987 Q91288 →
Q98949 — 0.987 Q98949 →
Q04589 — 0.986 Q04589 →
A0JM20 — 0.985 A0JM20 →
TNK1 Non-receptor tyrosine-protein kinase TNK1 0.985 landscape →
Q99ML2 — 0.984 Q99ML2 →
Q9YI66 — 0.984 Q9YI66 →
AXL Tyrosine-protein kinase receptor UFO 0.984 landscape →
Q61851 — 0.984 Q61851 →
Q63474 — 0.983 Q63474 →
Q9R011 — 0.983 Q9R011 →
EPHB4 Ephrin type-B receptor 4 0.983 landscape →
Q00993 — 0.983 Q00993 →
Q03146 — 0.983 Q03146 →
P08923 — 0.982 P08923 →
P0C0K6 — 0.982 P0C0K6 →
Q13308 — 0.982 Q13308 →
PLK3 Serine/threonine-protein kinase PLK3 0.982 landscape →
Q8C2S7 — 0.982 Q8C2S7 →
P18460 — 0.982 P18460 →
P70218 — 0.981 P70218 →
DDR1 Epithelial discoidin domain-containing receptor 1 0.981 landscape →
Q8K099 — 0.981 Q8K099 →